Poster Session 02

Treatment of high risk and oligo-metastatic prostate cancer

**Location:** Room Amsterdam, North Hall (Level 1)

**Chairs:**
- B.J. Challacombe, London (GB)
- S. Egawa, Tokyo (JP)
- R.J. Karnes, Rochester (US)

**Aims and objectives of this session**
The aim of this session is to evaluate outcomes of treatments in high risk and oligo-metastatic prostate cancer

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion.

17

Attempted nerve sparing in high risk prostate cancer: Does it have an impact on oncological and functional outcomes? A retrospective long-term single center study
By: Furrer M.A.¹, Gross T.¹, Nguyen D.P.¹, Boxler S.¹, Genitsch V.², Burkhard F.¹, Thalmann G.¹
Institutes: University Hospital Bern, Dept. of Urology, Bern, Switzerland, ²University Hospital Bern, Institute of Pathology, Bern, Switzerland

18

Impact of preoperative risk on metastatic progression and cancer specific death in patients with adverse pathology at radical prostatectomy
By: Boehm K.¹, Leyh-Bannurah S-R.², Rosenbaum C.², Budäus L.³, Graefen M.³, Haferkamp A.¹, Tilki D.³
Institutes: University Medical Center, Johannes Gutenberg University, Dept. of Urology and Pediatric Urology, Mainz, Germany, ²University Medical Center, Dept. of Urology, Hamburg, Germany, ³University Medical Center, Martini-Clinic, Hamburg, Germany

19

Low rate of positive surgical margins are not associated with improved biochemical recurrence in high-risk prostate cancer patients
By: Srougi V.¹, Sanchez-Salas R.¹, Secin F.², Baghdadi M.¹, Nunes-Silva I.¹, Garcia-Barreras S.¹, Rembeyo G.¹, Rozet F.¹, Galiano M.³, Barret E.¹, Cathelineau X.¹
Institutes: Institut Montsouris, Dept. of Urology, Paris, France, ²CEMIC and San Lazaro Foundation, Dept. of Urology, Buenos Aires, Argentina

20

Association between type 2 diabetes and curative treatment in men with intermediate and high risk localised prostate cancer
By: Crawley D.¹, Garmo H.¹, Rudman S.², Stattin P.³, Zethelius B.⁴, Holmberg L.¹, Adolfsson J.⁴, Van Hemelrijck M.¹
Institutes: King’s College London, Dept. of Cancer Epidemiology, London, United Kingdom, ²Guy’s and St Thomas NHS Foundation Trust, Dept. of Medical Oncology, London, United Kingdom, ³Uppsala University, Dept. of Surgical Sciences, Uppsala, Sweden, ⁴Karolinska Institute, Dept. of Clinical Science, Intervention and Technology, Stockholm, Sweden

21

Improved recurrence-free survival in locally advanced prostate cancer after robot-assisted radical prostatectomy with 3D-cancer mapping constructed by MRI/US fusion biopsy
By: Kamoi K., Okihara K., Hongo F., Naitoh Y., Iwata A., Kanazawa M., Ushijima S., Ukimura O.
Institutes: Kyoto Prefectural University of Medicine, Dept. of Urology, Kyoto, Japan

22

Assessing the 20-year outcomes of radical prostatectomy for high risk prostate cancer: Results from a large, multi-institutional series
By: Bianchi M.¹, Colicchia M.², Gandaglia G.², Munegato S.⁴, Fossati N.², Bandini M.², Stabile A.²,
Oncological and functional outcomes after RP for high or very high-risk prostate cancer – Impact of additional radiation and/or androgen deprivation therapy on functional outcomes after Predictors of early cancer specific and other cause mortality in high risk prostate cancer patients

Extended pelvic lymph node dissection for intermediate-high risk prostate cancer: Frequency and distribution of nodal metastases

Freedom from androgen deprivation and radiotherapy therapy after upfront minimally invasive surgery for high-risk prostate cancer

Survival associated with radical prostatectomy versus radiotherapy for high-risk prostate cancer: A contemporary, nationwide observational analysis

Impact of additional radiation and/or androgen deprivation therapy on functional outcomes after radical prostatectomy

Extended pelvic lymph node dissection for intermediate-high risk prostate cancer: Frequency and distribution of nodal metastases

Predictors of early cancer specific and other cause mortality in high risk prostate cancer patients after radical prostatectomy: Results from a large, multi-institutional analysis

Cytoreductive radical prostatectomy (cRP) is feasible in men with hormone-naive, metastatic prostate cancer (mPCA)
30

**Robot assisted radical prostatectomy in patients with oligometastatic prostate cancer**


**Institutes:** Yonsei University College of Medicine, Dept. of Urology and Urological Science Institute, Seoul, South Korea, National Health Insurance Corporation Ilsan Hospital, Dept. of Urology and Urological Science Institute, Goyang, South Korea, Inje University College of Medicine, Dept. of Urology and Urological Science Institute, Gimhae, South Korea

31

**Observation of preliminary clinical effect and analysis of perioperative complications of radical prostatectomy for patients with oligo-metastatic prostate cancer**

By: Li G., Dai B., Ye D.

**Institutes:** Fudan University Shanghai Cancer Center, Dept. of Urology, Shanghai, China